MEK抑制剂治疗非小细胞肺癌的研究进展

随着对肿瘤分子机制的深入研究，非小细胞肺癌的分子靶向治疗已获得重大进展。蛋白激酶抑制剂是新近研发的靶向药物之一，其通过阻碍细胞内分子传导，影响肿瘤细胞的生存与增殖而起作用。丝裂原细胞外激酶（mitogenextracellularkinase，MEK）在Ras／Raf／MEK／ERK信号通路中发挥重要作用，大量的基础及临床研究提示MEK广泛作用于多种信号通路并在各类实体肿瘤中过度表达，因此MEK抑制剂可能具备广谱的抗肿瘤的优势。本文以新型MEK抑制剂司美替尼（selumetinib，AZD6244，ARRXY-142886）为例，重点阐述Ras／Raf／MEK／ERK信号通路、MEK抑制剂的作用机制及研究进展。

Progress on MEK inhibitor therapy for non-small cell lung cancer

With the in-depth study on the molecular mechanism of tumor, molecular targeted treatment of non-small cell lung cancer has significant progress. As one of targeted drugs newly developed,protein kinase inhibitor plays roles by blocking the conduction of intracellular molecules and affecting the survival and proliferation of tumor cells. Mitogen extracellular kinase （MEK） is a pivotal molecule within the Ras/Raf/MEK/ERK signaling pathway. A large number of preelinical and clinical researches have shown that MEK plays a broad role in multiple signaling pathways,and is overexpressed in many types of solid tumors, therefore, MEK inhibitors may have broad-spectrum anti-tumor advantages. This review takes selumetinib （a novel MEK inhibitor） as an example to illustrate the mechanism and research progress of Ras/Raf/MEK/ERK signaling pathway and MEK inhibitor.